Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veritas In SilicoTSE:130A -0.96%13 PS Ratio is 72.22 as of Jul. 27, 2026, which is 13% above its 10-year median of 64.13. GuruFocus rates TSE:130A with a GF Score™ of 13/100. The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Veritas In Silico ranks worse than 82.45% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Veritas In Silico's share price is 円413.00.
Veritas In Silico's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円5.72. Hence, Veritas In Silico's PS Ratio for today is 72.22.
Good Sign:
Veritas In Silico Inc stock PS Ratio (=29.68) is close to 1-year low of 29.68.
The historical rank and industry rank for Veritas In Silico's PS Ratio or its related term are showing as below:
TSE:130A'
s PS Ratio Range Over the Past 10 Years
Min: 22.32 Med: 64.13 Max: 233.45
Current: 72.21
During the past 5 years, Veritas In Silico's highest PS Ratio was 233.45. The lowest was 22.32. And the median was 64.13.
TSE:130A's PS Ratio is ranked worse than 82.45% of 929
companies
in the Biotechnology industry
Industry Median: 9.03
vs TSE:130A: 72.21
During the past 5 years, Veritas In Silico's highest 3-Year average Revenue per Share Growth Rate was 48.00% per year. The lowest was -24.40% per year. And the median was 11.80% per year.
Back to Basics: PS Ratio
Veritas In Silico (TSE:130A) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Veritas In Silico PS Ratio Related Terms
Veritas In Silico PS Ratio Historical Data
* Premium members only.
The historical data trend for Veritas In Silico's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Veritas In Silico's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veritas In Silico PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veritas In Silico's PS Ratio distribution charts can be found below:
* The bar in red indicates where Veritas In Silico's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Veritas In Silico's Share Price of today is 円413.00. Veritas In Silico's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円5.72.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Veritas In Silico (TSE:130A) has a PS Ratio of 72.22 as of Jul. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Veritas In Silico and its competitors. This is 13% above median its historical median of 64.13. Over the past decade, Veritas In Silico's PS Ratio has ranged from 22.32 to 233.45. According to the industry distribution chart, Veritas In Silico ranks #766 out of 929 companies in the Biotechnology industry, placing it in the top 82.5%.
Is Veritas In Silico's PS Ratio too high?
Veritas In Silico's current PS Ratio of 72.22 is 13% above median its 10-year median of 64.13. Over the past 10 years, this metric has ranged from a low of 22.32 to a high of 233.45. The Biotechnology industry median PS Ratio is 9.03. Veritas In Silico's value of 72.22 is 699.8% above this industry median. Based on the distribution chart, Veritas In Silico ranks #766 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Veritas In Silico has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Veritas In Silico ranks #766 out of 929 companies for PS Ratio. This places Veritas In Silico in the lower half of its industry. The industry median PS Ratio is 9.03. Veritas In Silico's value of 72.22 is 699.8% above this benchmark. Historically, Veritas In Silico's own PS Ratio has ranged from 22.32 to 233.45 over the past decade. While the company's 10-year median is 64.13 vs. the industry median of 9.03, Veritas In Silico has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.03, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veritas In Silico's current PS Ratio of 72.22 is 699.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Veritas In Silico and its competitors. For the Biotechnology industry, the median PS Ratio is 9.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veritas In Silico's current PS Ratio is 72.22, which is 13% above median its own 10-year median of 64.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Veritas In Silico (TSE:130A) has a current PS Ratio of 72.22. The current PS Ratio is 72.22, which is 13% above median its 10-year median of 64.13 and 699.8% above the Biotechnology industry median of 9.03. Veritas In Silico's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current PS Ratio is 72.22 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
13GF Score
Get the complete analysis for TSE:130A
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:130A has been successfully added to your 
